Heterogeneous Vancomycin-Intermediate Susceptibility Phenotype in Bloodstream Methicillin-Resistant Staphylococcus aureus Isolates from an International Cohort of Patients with Infective Endocarditis: Prevalence, Genotype, and Clinical Significance
In-Gyu Bae, Jerome J Federspiel, Jose M Miro, Christopher W Woods, Lawrence Park, Michael J Rybak, Thomas H Rude, Suzanne Bradley, Suzana Bukovski, Cristina Garcia de la Maria, Souha S Kanj, Tony M Korman, Francesc Marco, David R Murdoch, Patrick Plesiat, Marta Rodriguez-Creixems, Porl Reinbott, Lisa Steed, Pierre Tattevin, Marie-Francoise Tripodi Show all
JOURNAL OF INFECTIOUS DISEASES | OXFORD UNIV PRESS INC | Published : 2009
BACKGROUND: The significance of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) is unknown. Using a multinational collection of isolates from methicillin-resistant S. aureus (MRSA) infective endocarditis (IE), we characterized patients with IE with and without hVISA, and we genotyped the infecting strains. METHODS: MRSA bloodstream isolates from 65 patients with definite IE from 8 countries underwent polymerase chain reaction (PCR) for 31 virulence genes, pulsed-field gel electrophoresis, and multilocus sequence typing. hVISA was defined using population analysis profiling. RESULTS: Nineteen (29.2%) of 65 MRSA IE isolates exhibited the hVISA phenotype by population analys..View full abstract
Awarded by National Institutes of Health
Awarded by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Financial support: Multiplex polymerase chain reaction and pulsed-field gel electrophoresis were funded by Cubist Pharmaceuticals (grant to C. W. W.). Population analyses were funded by Astellas (MRSA Center of Excellence grant to V. G. F., administered by Fallon Medica). Multilocus sequence typing were funded by the National Institutes of Health (grant R01-AI059111 to V. G. F.). The International Collaboration on Endocarditis Coordinating Center acknowledges the generous support of investigator donations from Bruno Barsic, G. R. C., V. G. F., David Gordon, and Andrew Wang and educational grants from Cubist Pharmaceuticals and the International Society of Cardiovascular Infectious Diseases.